Quetiapine monotherapy for bipolar depression

Bibliography

• Merikangas KE, Akiskal HS, Angst J, Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-52
   PubMed Web of Science ®Google Scholar
• Judd L, Akiskal HS, Schettler PJ, The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530-7
   PubMed Web of Science ®Google Scholar
• Judd L, Akiskal HS, Schettler PJ, A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60(3):216-69
   Google Scholar
• Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd edition. New York, New York: Oxford Press, 2007
   Google Scholar
• Marangell LB, Dennehy EB, Miyahara S, The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 2009;114(1-3):58-67
   PubMedGoogle Scholar
• Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74
   Google Scholar
• Grunze H, Vieta E, Goodwin GM, The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, Canadian Network for Mood Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55
   PubMed Web of Science ®Google Scholar
• Prozac (fluoxetine hydrochloride) Highlights of Prescribing Information [package insert]. Indianapolis, IN: Eli Lilly and Company, 2009
   Google Scholar
• Seroquel (quetiapine fumarate) Highlights of Prescribing Information [package insert]. Wilmington, DE: AstraZeneca, 2011
   Google Scholar
• Calabrese JR, Keck PE, Macfadden W, A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26(6):600-9
   PubMed Web of Science ®Google Scholar
• Weisler RH, Calabrese JR, Thase ME, Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008;69(5):769-82
   PubMedGoogle Scholar
• Vieta E, Calabrese JR, Goikolea JM, ; BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9(4):413-23
   PubMedGoogle Scholar
• Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. for the BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67(3):355-62
   PubMedGoogle Scholar
• Lydiard RB, Culpepper L, Schioler H, Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis or results from 2 double-blind, randomized, placebo-controlled studies. Prim Care Companion. J Clin Psychiatry 2009;11(5):215-25
   Google Scholar
• Endicott J, Paulsson B, Gustafsson U, Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 2008;111(2-3):306-19
   PubMedGoogle Scholar
• Young AH, McElroy SL, Bauer M, A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy S, Chang W, A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Presented at the 3rd Biennial Conference of the International Society for Bipolar Disorders, Delhi, India, January 27-28, 2008; Agra, India, January 20, 2008
   Google Scholar
• McElroy SL, Weisler RH, Chang W, A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74
   PubMedGoogle Scholar
• McElroy S, Olausson B, Chang W, A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II). Presented at the 3rd Biennial Conference of the International Society for Bipolar Disorders, Delhi, India, January 27-28, 2008; Agra, India, January 20, 2008
   Google Scholar
• Suppes T, Datto C, Minkwitz M, Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121(1-2):106-15
   PubMedGoogle Scholar
• DelBello MP, Chang K, Welge JA, A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009;11(5):483-93
   PubMedGoogle Scholar
• Perlis RH, Ostacher M, Fava M, Assuring that double-blind is blind. Am J Psychiatry 2010;167(3):250-2
   PubMedGoogle Scholar
• Baker RW, Tohen M, Fawcett J, Acute dysphoric mania: Treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132-7
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Sachs GS, Baldassano CF, Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997;42:196-9
   PubMed Web of Science ®Google Scholar
• Vieta E, Giokolea JM, Corbella B, Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a six-month, multi-center open study. J Clin Psychiatry 2001;62:818-25
   PubMed Web of Science ®Google Scholar
• Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65(12):1715-19
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002;63:1156-63
   PubMed Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Nelson JC, Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008;10(6):440-7
   PubMedGoogle Scholar
• Suppes T, Vieta E, Liu S, ; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166(4):476-88
   PubMedGoogle Scholar
• Vieta E, Suppes T, Eggens I, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International trial 126). J Affect Disord 2008;109(3):251-63
   PubMedGoogle Scholar
• Janicak PG, Marder S, Pavuluri M, Principles and Practice of Psychopharmacotherapy. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2011
   Google Scholar